Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company, highlighting its revenue structure, market position, and recent financial results. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, operates in the heparin industry, biopharmaceutical CDMO, and innovative drug development, aiming to provide high-quality medications globally [2][7]. - The company has a dual financing platform (A+H shares) and focuses on the production and commercialization of heparin and other pharmaceutical products [2][7]. Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On August 12, Haiprime's stock price decreased by 0.53%, with a trading volume of 56.64 million yuan and a market capitalization of 19.178 billion yuan [1]. - The stock's average trading cost is 11.35 yuan, with current price levels between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with both increasing their holdings [8].

Investment Rating - The report indicates a focus on potential business development opportunities in the weight loss drug sector, suggesting a positive outlook for innovative drug companies in this area [1][2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.84% from August 4 to August 8, underperforming compared to the Wind All A index (1.94%) and the CSI 300 index (1.23%) [7][9]. - Notable sub-sectors that performed well include medical consumables (3.93%), in vitro diagnostics (2.55%), and medical devices (1.94%), while medical research outsourcing (-3.56%), chemical preparations (-2.04%), and traditional Chinese medicine (-1.88%) saw significant declines [8][10]. - The report highlights the competitive landscape in the weight loss drug pipeline, with Eli Lilly reaffirming the feasibility of oral GLP-1 drugs, while other multinational corporations (MNCs) may seek external products to enhance competitiveness [2][12]. - The report also discusses the initiative by seven government departments to promote innovation in the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector saw a decline of 0.84% during the week, with significant internal rotation and underperformance compared to broader indices [7][9]. - Medical consumables, in vitro diagnostics, and medical devices were the top-performing sub-sectors, while medical research outsourcing and chemical preparations faced the largest declines [8][10]. Industry News and Key Company Announcements - The report notes several key industry events, including the approval of a biosimilar drug by Boan Biotech and the joint initiative by multiple government departments to foster the brain-computer interface industry [11][12]. - Significant company announcements include the approval of new indications for existing drugs and the launch of new products, indicating ongoing innovation within the sector [15][16].

Core Viewpoint - China National Pharmaceutical Group announced the convening of its 30th board meeting on August 8, 2025, to review various proposals, including amendments to existing documents [2] Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Group is as follows: - Pharmaceutical commerce accounts for 77.31% - Pharmaceutical trade accounts for 14.35% - Chemical preparations account for 4.47% - Raw materials account for 2.78% - Traditional Chinese medicine accounts for 1.47% [2]

Group 1 - The report tracks stocks, industries, and sectors that are reaching new highs, indicating market trends and hotspots [1][4][26] - As of August 8, 2025, the distance to the 250-day new high for major indices is as follows: Shanghai Composite Index 0.12%, Shenzhen Component Index 3.19%, CSI 300 3.55%, CSI 500 0.53%, CSI 1000 0.35%, CSI 2000 0.23%, ChiNext Index 8.48%, and STAR 50 Index 7.39% [6][26] - The industries closest to their 250-day new highs include machinery, non-ferrous metals, basic chemicals, light industry manufacturing, and textile and apparel, while food and beverage, coal, real estate, consumer services, and comprehensive finance are further away [9][26] Group 2 - A total of 1,336 stocks reached a 250-day new high in the past 20 trading days, with the most in the pharmaceutical, machinery, and basic chemicals sectors [2][14][26] - The highest proportion of new high stocks is found in the steel, defense, and non-ferrous metals industries, with respective proportions of 54.72%, 47.06%, and 43.55% [14][16] - The manufacturing and cyclical sectors had the most new high stocks this week, with 437 and 310 stocks respectively [16][26] Group 3 - The report identifies 50 stable new high stocks based on analyst attention, relative strength, trend continuity, price path stability, and new high sustainability [3][21][27] - The manufacturing sector had the most stable new high stocks, particularly in the machinery industry, while the cyclical sector's highest was in basic chemicals [21][27]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 1.80% from July 25, 2025, to August 7, 2025, exceeding the CSI 300 index by approximately 2.62 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and chemical preparation sectors leading with increases of 6.32% and 4.33%, respectively [13]. - Approximately 61% of stocks in the industry achieved positive returns, with notable performers such as Lide Man, which saw a weekly increase of 71.70% [14][17]. - The overall industry valuation remains stable, with a PE (TTM) of approximately 52.61 times as of August 7, 2025, which is relatively low compared to historical levels [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 1.80% from July 25, 2025, to August 7, 2025, surpassing the CSI 300 by about 2.62 percentage points [12]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and chemical preparations, which increased by 6.32% and 4.33%, while hospitals and vaccines saw declines of 1.88% and 1.76% [13]. - About 61% of stocks in the industry posted positive returns, with Lide Man leading at a 71.70% increase [14][17]. 2. Industry News - The 11th batch of national drug procurement officially began reporting on August 6, 2025, with key deadlines for data submission and review set for August 25 and August 27, respectively [24]. 3. Company Announcements - Yifan Pharmaceutical announced that its subsidiary received a drug registration acceptance notice for melatonin granules, marking a significant milestone as the first domestic application for this product [25]. 4. Weekly Industry Perspective - The report maintains an "Overweight" rating for the industry, highlighting the continuous outperformance of the pharmaceutical and biotechnology sector against the CSI 300 index, driven by new business development (BD) authorizations and positive earnings forecasts from medical research outsourcing companies [26][28].

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-share companies is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanxia from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

责任编辑：公司观察 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-20 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各 ...

从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 其中，年薪排行前三的CFO分别为迪哲医药的吕洪斌、丽珠集团的司燕霞、科伦药业的赖德贵，三人年 薪分别为421.01万元、390.40万元、300 ...